Ibicuruzwa Bishyushye Semaglutide CAS 910463-68-2 Ashyushye

Intangiriro kuri Somaglutide

Somaglutide ni igisekuru gishya cya GLP-1 (glucagon nka peptide-1) igereranya ryakozwe na Daminol na NovoNordisk.Somaglutide nuburyo bwa dosiye ndende ikora yakozwe ishingiye kumiterere shingiro ya Lilalutide, igira ingaruka nziza mukuvura diyabete yo mu bwoko bwa 2.Novo Nordisk yarangije ubushakashatsi 6 bwa PChemicalbookbaseIIIa ku bijyanye no guterwa inshinge za Somaglutide, anatanga icyifuzo gishya cyo kwandikisha ibiyobyabwenge cyo gutera inshinge Somaglutide buri cyumweru mu kigo gishinzwe ibiryo n'ibiyobyabwenge muri Amerika (FDA) ku ya 5 Ukuboza 2016, ndetse no gusaba uruhushya rwo kwamamaza (MAA) kuri ibiyobyabwenge byo mu Burayi A.ubuyobozi (EMA).Ku rundi ruhande, gutegura rimwe mu kanwa kwa Somaglutide kuri ubu biri mu cyiciro cya III.

Ikoreshwa

Somaglutide ni dosiye ndende ikora ikora ishingiye kumiterere shingiro ya liraglutide, igira ingaruka nziza mukuvura diyabete yo mu bwoko bwa 2.

Ubushakashatsi

Semeglutide nikigereranyo gishya cya GLP-1 cyatewe inshinge munsi yicyumweru.Somaglutide nikigereranyo kirekire-GLP-1 cyakozwe na Novo Nordisk kumwanya umwe / w inshinge zidasanzwe.Ugereranije na liraglutide, Somaglutide ifite urunigi rurerure kandi rwongera hydrophobicity.Nyamara, Somaglutide yahinduwe hamwe numurongo mugufi PEG, kandi hydrophilicity yayo irazamuka cyane.Nyuma yo guhindura PEG, ntishobora guhuza gusa na albumin, gupfukirana hydrolysis ya enzyme ya DPP-4, ariko kandi igabanya gusohora impyiko, ikongerera ubuzima igice cya kabiri cyubuzima kandi ikagera ku ngaruka zigihe kirekire.Somaglutide ya Novo Nordisk yamanitse DPP-4′s Sigliptin, na GLP-1′s watangije, exenatide ikora igihe kirekire (igomba kuba yarateguwe kugirango irushanwe imitwe n'umutwe wa Lily. Gutotezwa bimaze igihe kinini ku isoko).Mu bushakashatsi, urugero rwinshi rwa Somicalbook rwaragabanutse A1C1,6%, kandi ibiro byinshi byari ibiro 6.Somaglutide yakoreshejwe mu gukora iperereza ku mikorere n’umutekano bya 1.0mg Somaglutide ugereranije na 2.0mg Exenatide rimwe mu cyumweru ku barwayi 813 barwaye diyabete yo mu bwoko bwa 2.Igihe cyo kugerageza cyari ibyumweru 56, kandi abarwayi bafashe imiti 1-2 yo kurwanya diyabete icyarimwe.Ukuboza 2017, FDA yemeye ku mugaragaro imiti ya GLP-1 ya hypoglycemic Somaglutide yakozwe na NovoNordisk igurishwa ku izina ry’ubucuruzi Ozempic.Dukurikije imibare y’ubuvuzi, Ozempic irashobora kugabanya urwego rwa HbA1c ugereranije na placebo, Januvia ya Merck, Bydureon wa AstraZeneca na Lantus ya Sanofi.Uyu muti kandi werekanye ubushobozi bwo gufasha abarwayi guta ibiro.